We are live on ! Find out more
NVNO

enVVeno Medical

3 hedge funds and large institutions have $240K invested in enVVeno Medical in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 33 (0)

0% more ownership

Funds ownership: 0%0% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

2% less capital invested

Capital invested by funds: $244K → $240K (-$4K)

Holders
3
Holders Change
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
1
Reduced
Closed
1
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$141K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$4.74K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$10K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$154K +$4.74K +3 +2%
Jane Street
2
Jane Street
New York
$81K +$141K +89 New
FIA
3
FNY Investment Advisers
New York
$5K
UBS Group
4
UBS Group
Switzerland
-$10K -8 Closed

NVNO Hedge Fund Activity: Q2 2019 in Review

3 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in enVVeno Medical (NVNO) for Q2 2019, worth a combined $240K — down 1.6% from $244K a quarter earlier.

Fund positioning in NVNO was balanced in Q2 2019: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $141K. The largest seller was UBS Group, exiting entirely with an estimated $10K sold.

  • 3 institutional investors held enVVeno Medical (NVNO) as of Q2 2019, unchanged from Q1 2019.
  • Funds reported $240K of enVVeno Medical stock for Q2 2019, down 1.6% quarter-over-quarter.
  • 1 fund opened new enVVeno Medical positions in Q2 2019 and 1 closed out, a net change of 0 holders.
  • The largest enVVeno Medical buyer in Q2 2019 was Jane Street, an estimated $141K added.
  • The largest enVVeno Medical seller in Q2 2019 was UBS Group, an estimated $10K sold.

Based on aggregated 13F filings for Q2 2019.